On May 29, WuXi Biologics rose 3.15% in regular trading, trading at HK$33.2 per share, with trading volume of approximately HK$80.78 million.

On the news front, the company resolved on May 24 to deploy its buyback authorization to repurchase shares on the open market at a total price not exceeding USD 400 million, covering up to 407 million shares representing 10% of total issued shares. Management explicitly stated that the current share price does not reflect the company's intrinsic value or actual business prospects.

The buyback plan has entered active execution. On May 27, the company spent approximately HK$49.91 million to repurchase 1.4715 million shares, followed by another HK$49.89 million for 1.5345 million shares on May 28, totaling over 3 million shares repurchased in two days. Additionally, the company recently announced its 18th formulation production facility has received GMP certification, reinforcing its end-to-end CDMO capabilities and global supply chain resilience.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)